Digital twin platform provider Unlearn.AI has partnered with German clinical research platform APST Research to integrate data from over 8,000 amyotrophic lateral sclerosis (ALS) patients into Unlearn's Digital Twin Generator (DTG).

The partnership will incorporate APST's comprehensive dataset, which includes clinical data, patient self-assessments, biomarker analyses, and common ALS clinical assessments, into Unlearn's platform. This collaboration marks APST's first dataset licensing agreement and will enable both companies to work on future research publications while supporting clinical trials with digital twins at various stages, from design and planning to execution and analysis.

Analyst QuickTake: Unlearn has continuously expanded its DTG capabilities through partnerships during the past year. In September 2024, it partnered with ProJenX to leverage its DTG technology in ProJenX’s PRO-101 Phase I trial of prosetin, and in June 2023 , it partnered with QurAlis for ALS therapy trials.